NCT05963074 2026-03-13
TAILOR
Janssen Research & Development, LLC
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT04509700 2025-12-10
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Incyte Corporation
Phase 2 Active not recruiting
NCT05105841 2025-10-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2 Completed
NCT04477486 2025-07-09
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
AbbVie
Phase 2 Completed
NCT04062448 2025-05-25
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
Janssen Pharmaceutical K.K.
Phase 2 Completed
NCT02910583 2024-12-20
Captivate
Pharmacyclics LLC.
Phase 2 Completed
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT01109069 2020-05-27
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 2 Completed
NCT02902965 2020-03-16
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Pharmacyclics Switzerland GmbH
Phase 2 Completed
NCT01478581 2020-03-10
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Pharmacyclics LLC.
Phase 2 Completed
NCT01980628 2019-10-16
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02351037 2018-08-14
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
Pharmacyclics LLC.
Phase 2 Terminated
NCT01779791 2017-07-18
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT01325701 2017-03-31
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT02169180 2017-01-24
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Janssen Pharmaceutical K.K.
Phase 2 Completed
NCT01599949 2016-06-01
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT01236391 2015-08-28
PCYC-1104-CA
Pharmacyclics LLC.
Phase 2 Completed